Evommune licenses Hinova's oral VAV1 degrader for autoimmune disease
- Evommune obtained rights outside Greater China to EVO570, Hinova's oral molecular glue degrader aimed at VAV1, an immune-cell signaling protein.
- Hinova receives $30M upfront ($20M cash plus $10M in pre-funded warrants), with milestones up to $1.1B and royalties on sales outside China.
- Rheumatoid arthritis is the lead indication; the deal follows Evommune's discontinuation of EVO756 in two skin diseases.
💡 Points Based on public reports
This reads as pipeline triage: after EVO756 failed in two skin diseases, Evommune buys a new story rather than waiting. The $30M upfront, a third of it in warrants, against $1.1B in milestones is a cheap option on an unproven target. VAV1 degradation is a bet that oral glues can out-position injectable biologics in rheumatoid arthritis. It also shows Chinese biotechs becoming default sources of ex-China assets.
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap ↗